Coassembly of Hypoxia-sensitive Macrocyclic Amphiphiles and Extracellular Vesicles for Targeted Kidney Injury Imaging and Therapy
Overview
Authors
Affiliations
Background: Hypoxia is a major contributor to global kidney diseases. Targeting hypoxia is a promising therapeutic option against both acute kidney injury and chronic kidney disease; however, an effective strategy that can achieve simultaneous targeted kidney hypoxia imaging and therapy has yet to be established. Herein, we fabricated a unique nano-sized hypoxia-sensitive coassembly (Pc/C5A@EVs) via molecular recognition and self-assembly, which is composed of the macrocyclic amphiphile C5A, the commercial dye sulfonated aluminum phthalocyanine (Pc) and mesenchymal stem cell-excreted extracellular vesicles (MSC-EVs).
Results: In murine models of unilateral or bilateral ischemia/reperfusion injury, MSC-EVs protected the Pc/C5A complex from immune metabolism, prolonged the circulation time of the complex, and specifically led Pc/C5A to hypoxic kidneys via surface integrin receptor αβ and αβ, where Pc/C5A released the near-infrared fluorescence of Pc and achieved enhanced hypoxia-sensitive imaging. Meanwhile, the coassembly significantly recovered kidney function by attenuating cell apoptosis, inhibiting the progression of renal fibrosis and reducing tubulointerstitial inflammation. Mechanistically, the Pc/C5A coassembly induced M1-to-M2 macrophage transition by inhibiting the HIF-1α expression in hypoxic renal tubular epithelial cells (TECs) and downstream NF-κB signaling pathway to exert their regenerative effects.
Conclusion: This synergetic nanoscale coassembly with great translational potential provides a novel strategy for precise kidney hypoxia diagnosis and efficient kidney injury treatment. Furthermore, our strategy of coassembling exogenous macrocyclic receptors with endogenous cell-derived membranous structures may offer a functional platform to address multiple clinical needs.
Emerging Frontiers in acute kidney injury: The role of extracellular vesicles.
Li S, Zhou L, Huang Y, Tang S Bioact Mater. 2025; 48:149-170.
PMID: 40046015 PMC: 11880721. DOI: 10.1016/j.bioactmat.2025.02.018.
Recent advances of photoresponsive nanomaterials for diagnosis and treatment of acute kidney injury.
Yao S, Wang Y, Mou X, Yang X, Cai Y J Nanobiotechnology. 2024; 22(1):676.
PMID: 39501286 PMC: 11536863. DOI: 10.1186/s12951-024-02906-6.
The Application of Drugs and Nano-Therapies Targeting Immune Cells in Hypoxic Inflammation.
Luo J, Wang H, Chen J, Wei X, Feng J, Zhang Y Int J Nanomedicine. 2024; 19:3441-3459.
PMID: 38617798 PMC: 11015843. DOI: 10.2147/IJN.S456533.
Engineered Extracellular Vesicles in Chronic Kidney Diseases: A Comprehensive Review.
Xue K, Mi B Int J Nanomedicine. 2024; 19:2377-2393.
PMID: 38469058 PMC: 10926925. DOI: 10.2147/IJN.S452393.
Dual hypoxia-responsive supramolecular complex for cancer target therapy.
Guo J, Li J, Wang Z, Liu Y, Yue Y, Li H Nat Commun. 2023; 14(1):5634.
PMID: 37704601 PMC: 10500001. DOI: 10.1038/s41467-023-41388-2.